Why Are Some IL-23 Biologics More Effective for Psoriasis? Dive into the molecular mechanisms behind IL-23 biologics and discover what sets certain treatments apart in managing moderate to severe psoriasis. This new article from the Journal of Drugs in Dermatology breaks down key structural insights that could impact your clinical decisions. Stay ahead in the evolving world of biologics and optimize care for your patients. Read the full article now: 🔗 https://lnkd.in/eQWtdSAi #Dermatology #Psoriasis #Biologics #IL23 #ClinicalDerm #JDD #MedicalResearch
Journal of Drugs in Dermatology (JDD)’s Post
More Relevant Posts
-
Why Are Some IL-23 Biologics More Effective for Psoriasis? Dive into the molecular mechanisms behind IL-23 biologics and discover what sets certain treatments apart in managing moderate to severe psoriasis. This new article from the Journal of Drugs in Dermatology breaks down key structural insights that could impact your clinical decisions. Stay ahead in the evolving world of biologics and optimize care for your patients. Read the full article now: 🔗 https://lnkd.in/eD_wSsbw #Dermatology #Psoriasis #Biologics #IL23 #ClinicalDerm #JDD #MedicalResearch
-
-
Associate Professor of Dermatology and Translational Biomedicine at Yale University School of Medicine
📢 New Publication: “Structural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis” recently published in Journal of Drugs in Dermatology (JDD). In this article, we summarize a work that explores the structural properties of IL-23 biologics and their correlation with clinical efficacy in treating moderate and severe plaque psoriasis. Key factors examined include epitope surface area, binding affinity, and dissociation rates, which help explain why some biologics outperform others. Key findings: Risankizumab has the largest epitope surface area, stronger binding affinity and higher PASI-90 response rates compared to other IL-23 inhibitors. Clinical Implications: 1- Drug selection: These insights may assist clinicians in choosing biologics for patients who require robust efficacy and less frequent dosing. 2- Biologic switching: For patients not responding to one IL-23 inhibitor, switching to another, such as risankizumab, might still be effective due to distinct molecular characteristics. The study contributes to a deeper understanding of IL-23 biologics and their role in optimizing psoriasis treatment strategies. #Psoriasis #Dermatology #IL23 #Biologics #Research #Insights
Why Are Some IL-23 Biologics More Effective for Psoriasis? Dive into the molecular mechanisms behind IL-23 biologics and discover what sets certain treatments apart in managing moderate to severe psoriasis. This new article from the Journal of Drugs in Dermatology breaks down key structural insights that could impact your clinical decisions. Stay ahead in the evolving world of biologics and optimize care for your patients. Read the full article now: 🔗 https://lnkd.in/eD_wSsbw #Dermatology #Psoriasis #Biologics #IL23 #ClinicalDerm #JDD #MedicalResearch
-
-
🚀 Exciting Growth in the Prescription Dermatology Therapeutics Market! 🚀 Get More Details: https://shorturl.at/x32tM The #Prescription #Dermatology #Therapeutics Market is projected to reach an impressive $79.11 billion by the end of the forecast period, growing at a robust CAGR of 9.5%. 🌟 Key drivers for this growth include: 🔹 High incidence and prevalence of infectious and chronic dermatological disorders. 🔹 Continuous novel drug development worldwide. Our skin, the body's largest and most exposed organ, faces constant threats from various toxins and microbes. This highlights the critical need for advanced dermatological treatments. Stay tuned for more updates on how this dynamic market is evolving! Prescription Dermatology Therapeutics Market, Key Players are: AbbVie Janssen Biotech, Inc. Novartis Amgen #Dermatology #Healthcare #Pharmaceuticals #MarketGrowth #Innovation
-
-
Read the blog: https://ow.ly/tthf50SPm2Q Discover the latest insights in psoriasis treatment with our new blog post: “A Matching-Adjusted Indirect Comparison (MAIC) of Guselkumab Versus Risankizumab in Patients With Moderate-to-Severe Plaque Psoriasis” by Barkha Patel, PhD and Tim Disher. This study emphasizes the importance of ITCs in guiding optimal treatment strategies for PsO. Dive deeper into the findings and their implications for clinical decision-making. #Psoriasis #Dermatology #Biologics #Guselkumab #Risankizumab #HEOR #ClinicalInsights #MAIC
-
-
Where will emerging #biologics fit into the #atopicdermatitis algorithm? As the American Academy of Dermatology meeting approaches, FirstWord will host a call with a KOL to discuss #emergingtrends in the treatment of atopic dermatitis. Learn more here: https://lnkd.in/dUKJmMYQ #clinicalresearch #dermatitis #pharmaceuticals
-
Don't miss our live 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗼𝗻 𝗗𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝘆 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 & 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁! 👉 REGISTER HERE: https://lnkd.in/eR_P94BN QIMA Life Sciences Newtone Technologies #drugdevelopment #dermatology #pharma #webinar
[WEBINAR] 📅 We are excited to invite you to our upcoming free #LiveWebinar on July 11th at 4 p.m. In this webinar, our experts will lead you through the #DrugDiscovery and #Development process, showcasing insightful dermatology case studies where we have helped clients achieve their research goals. 💡 Discover how our established and custom-developed models and tests contributed to the success of other projects - and see how they can benefit yours next! 👩🔬 If you work in the field of #Dermatology, or are simply interested in learning more about it, this is an opportunity you won't want to miss! This webinar will be presented by Séverine Thibaut de Ménonville 🧪 🧬 from QIMA Life Sciences, Marta Bertolini, PhD from Monasterium Laboratory Skin & Hair Research Solutions GmbH, and Jean-Michel Delaval from Newtone Technologies. 🖱 CLICK HERE TO REGISTER: https://lnkd.in/eR_P94BN #Healthcare #Pharma #Pharmaceutical #Research #ClinicalTrials
-
-
Don't miss our live 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗼𝗻 𝗗𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝘆 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 & 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁! 👉 REGISTER HERE: https://lnkd.in/eR_P94BN #drugdevelopment #dermatology #pharma #webinar
[WEBINAR] 📅 We are excited to invite you to our upcoming free #LiveWebinar on July 11th at 4 p.m. In this webinar, our experts will lead you through the #DrugDiscovery and #Development process, showcasing insightful dermatology case studies where we have helped clients achieve their research goals. 💡 Discover how our established and custom-developed models and tests contributed to the success of other projects - and see how they can benefit yours next! 👩🔬 If you work in the field of #Dermatology, or are simply interested in learning more about it, this is an opportunity you won't want to miss! This webinar will be presented by Séverine Thibaut de Ménonville 🧪 🧬 from QIMA Life Sciences, Marta Bertolini, PhD from Monasterium Laboratory Skin & Hair Research Solutions GmbH, and Jean-Michel Delaval from Newtone Technologies. 🖱 CLICK HERE TO REGISTER: https://lnkd.in/eR_P94BN #Healthcare #Pharma #Pharmaceutical #Research #ClinicalTrials
-
-
Join Genemarkers’ Anna Langerveld and Jocelyn K. at the 8th Annual Dermatology Drug Development Summit on November 12-14, 2024 in Boston. This is a great opportunity to learn how Genemarkers’ services can improve your drug development. To connect with Anna and Jocelyn during the event, email jkearsley@genemarkersllc.com or schedule a meeting directly: https://lnkd.in/ePKXEseV #Dermatology #Dermatologics #DermatologyMedication #TopicalDermatology #DermatologyDrug #DrugDevelopment #Pharma #Pharmaceuticals #SkinScience #Skincare #DermalPharma #DermalResearch #DrugDiscovery #Preclinical #PreclinicalResearch #ClinicalTrial #ClinicalResearch
-
-
What is Nemolizumab? Another wonder drug for Prurigo Nodularis undergoing approval process. Great news for patients that they will soon (pending FDA approval of Nemolizumab) have 2 biologics- Dupilumab and Nemolizumab for their skin condition! Learn more about biologics and small molecule targeted therapies and stay abreast of the latest in Specialty pharmacy practice at Prosperx. #specialtypharmacy #retailpharmacy #independentpharmacy #pharmacy #pharmacytechnician #dermatology #dermatologist
-
